38
Participants
Start Date
September 9, 2022
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2024
IO-108
IO-108, intravenously, on Day 1 of each 21-day cycle.
IO-108 + pembrolizumab
IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
IO-108 + tislelizumab
IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
Shanghai Dong Fang Hospital, Shanghai
Shandong Cancer Hospital, Jinan
The First Affiliated Hospital of Nanchang University, Nanchang
Hunan Cancer Hospital, Changsha
The First Affiliated Hospital of Fujian Medical University, Fujian
1st affiliated Hospital of Hainan Medical University, Haikou
4th Hospitla of Hebei Medical University, Shijiazhuang
Harbin Cancer Hospital, Harbin
Henan Cancer Hospital, Zhengzhou
Tongji Hospital, Wuhan
Liaoning Cancer Hospital, Shenyang
Lin Yi Cancer Hospital, Linyi
1st Affiliated Hospital of Xi'an Jiaotong University, Xian
Sir RUN RUN SHAW HOSPITAL, Hangzhou
Lead Sponsor
Immune-Onc Therapeutics
INDUSTRY